TRIAL DETAIL
A Dose-Escalation Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-573 in Subjects With Advanced Solid Tumors
Drug: |
||||
|---|---|---|---|---|
Trial Name: |
A Dose-Escalation Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-573 in Subjects With Advanced Solid Tumors |
|||
NCT#: |
||||
Conditions: |
Solid Tumors |
|||
Status: |
Ongoing, but not recruiting |
|||
Phase: |
1 |
Start Date 03/01/2009 |
Age of Trial (yrs) 16.1 |
|
Treatment Phase: |
Gleevec-resistant |
|||
Drug Category: |
IGF1R inhibitor |
|||
Strategy: |
Block related tumor signal paths |
|||
Trial Type: |
GIST not specified. GIST patient enrollment unknown. |
|||
Other Protocol IDs: |
MI-CP184 |
|||
Sponsor: |
MedImmune LLC |
|||
Patient Contact: |
Oncology Research
Oncologyresearchstud@Medimmune.com |
|||
Contact email: |
||||
Contact Phone: |
||||
Randomized: |
||||
IV or Oral: |
Intravenous |
|||
Trial Notes: |
||||
Trial Links |
Trial Results |
Drug Information |
Trial Sites
Name |
Address |
City |
State |
Zip |
Country |
Jacksonville |
FL |
32224 |
USA |
||
4100 John R |
Detroit |
MI |
48201 |
USA |
|
Rochester |
MN |
55905 |
USA |